Compare Quest Diagnostics Inc (DGX) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI China ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while iShares MSCI China ETF trades at $53.71. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares MSCI China ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| DGX | MCHI | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $66.99 |
52-Week Low | $166.42 | $50.48 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
MCHI trades at $52.53, down 1.13% on the day, with neutral technical signals from both moving averages and oscillators. The ETF shows mixed sentiment amid China's factory rebound driven by AI hardware exports and Beijing's $295 billion AI infrastructure plan. Recent news highlights China's tech sector momentum but also persistent geopolitical tensions with US restrictions on Chinese tech firms.
Outlook remains balanced with AI-driven growth potential offset by value trap risks and regulatory uncertainties. The ETF faces headwinds from US-China tech rivalry but benefits from China's massive domestic AI investment program. Investors should weigh sector-specific opportunities against broader macroeconomic and geopolitical challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
